Voya Investment Management LLC Has $438,000 Stock Holdings in AtriCure, Inc. (NASDAQ:ATRC)

Voya Investment Management LLC lowered its holdings in AtriCure, Inc. (NASDAQ:ATRC) by 7.5% during the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 14,321 shares of the medical device company’s stock after selling 1,158 shares during the quarter. Voya Investment Management LLC’s holdings in AtriCure were worth $438,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in ATRC. Adage Capital Partners GP L.L.C. acquired a new stake in AtriCure during the fourth quarter worth about $9,168,000. Kennedy Capital Management LLC grew its holdings in shares of AtriCure by 29.8% during the 4th quarter. Kennedy Capital Management LLC now owns 752,580 shares of the medical device company’s stock worth $22,999,000 after purchasing an additional 172,648 shares in the last quarter. Marshall Wace LLP increased its position in shares of AtriCure by 37.1% during the fourth quarter. Marshall Wace LLP now owns 619,166 shares of the medical device company’s stock valued at $18,922,000 after purchasing an additional 167,476 shares during the period. Dimensional Fund Advisors LP raised its stake in shares of AtriCure by 24.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 700,212 shares of the medical device company’s stock valued at $21,398,000 after purchasing an additional 136,015 shares in the last quarter. Finally, Raymond James Financial Inc. bought a new position in AtriCure in the fourth quarter worth $3,716,000. 99.11% of the stock is owned by institutional investors.

AtriCure Stock Performance

Shares of NASDAQ:ATRC opened at $30.99 on Friday. The business has a fifty day moving average of $32.71 and a 200-day moving average of $34.78. The firm has a market cap of $1.53 billion, a PE ratio of -32.62 and a beta of 1.57. The company has a debt-to-equity ratio of 0.13, a quick ratio of 2.62 and a current ratio of 3.65. AtriCure, Inc. has a twelve month low of $18.94 and a twelve month high of $43.11.

AtriCure (NASDAQ:ATRC) last announced its earnings results on Tuesday, April 29th. The medical device company reported ($0.14) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.11. The company had revenue of $123.62 million for the quarter, compared to analyst estimates of $122.92 million. AtriCure had a negative net margin of 9.61% and a negative return on equity of 6.80%. AtriCure’s quarterly revenue was up 13.5% on a year-over-year basis. During the same period in the prior year, the business earned ($0.28) earnings per share. On average, equities research analysts predict that AtriCure, Inc. will post -0.6 EPS for the current fiscal year.

Insider Activity

In other news, Director Karen Prange sold 6,100 shares of the company’s stock in a transaction on Wednesday, March 5th. The stock was sold at an average price of $38.12, for a total transaction of $232,532.00. Following the transaction, the director now owns 17,828 shares of the company’s stock, valued at $679,603.36. This represents a 25.49 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Insiders own 3.50% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of equities analysts have recently commented on the stock. BTIG Research reaffirmed a “buy” rating on shares of AtriCure in a report on Thursday, March 27th. JMP Securities restated a “market outperform” rating and set a $60.00 price target on shares of AtriCure in a research note on Wednesday, April 30th. Needham & Company LLC decreased their price objective on AtriCure from $51.00 to $44.00 and set a “buy” rating on the stock in a report on Wednesday, April 30th. UBS Group dropped their target price on AtriCure from $60.00 to $58.00 and set a “buy” rating for the company in a report on Wednesday, April 30th. Finally, JPMorgan Chase & Co. decreased their price target on AtriCure from $51.00 to $46.00 and set an “overweight” rating on the stock in a research note on Thursday, March 27th. One equities research analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, AtriCure currently has an average rating of “Moderate Buy” and a consensus target price of $50.67.

AtriCure Company Profile

AtriCure, Inc develops, manufactures, and sells devices for surgical ablation of cardiac tissue, exclusion of the left atrial appendage, and temporarily blocking pain by ablating peripheral nerves to medical centers in the United States, Europe, the Asia-Pacific, and internationally. The company offers Isolator Synergy Clamps, single-use disposable radio frequency products; multifunctional pens and linear ablation devices, such as the MAX Pen device that enables surgeons to evaluate cardiac arrhythmias, perform temporary cardiac pacing, sensing, and stimulation, and ablate cardiac tissue with the same device; and the Coolrail device, which enables users to make longer linear lines of ablation.